EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In Vitro–In Vivo Correlation-Based Evaluation of Bioequivalence in Commercial Paracetamol Brands in Nigeria

Galadima Isa Hayatu, Durojaye Bisoye Aishat, Folashade Blessing Adeloye, Mustapha Bolanle Kudirat, Olayemi Olubunmi Jumoke, Isaac Johnson Ajeh

The Nigerian Journal of Pharmacy · 30.10.2025 · 59 (2) · 327-339

DOI: 10.51412/psnnjp.2025.33 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Nigerian Journal of Pharmacy, online erschienen am 30.10.2025. Verfasst von Galadima Isa Hayatu und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paracetamol is a widely used over-the-counter analgesic and antipyretic in Nigeria. Ensuring the quality and therapeutic consistency of oral paracetamol products is a critical public health concern. Bioequivalence assessment is essential to confirm that generic drugs match the reference product in terms of rate and extent of systemic drug exposure. Methodology: This study employed a convolution-based in vitro-in vivo correlation (IVIVC) model to evaluate the bioequivalence of 18 commercial paracetamol tablet brands marketed in Nigeria. The physicochemical properties of the tablets were evaluated, and in vitro dissolution tests were conducted. The IVIVC model was used to predict the pharmacokinetic parameters of the tablets.

Results

While most products met basic pharmacopeia standards for assay, disintegration and dissolution, none reached full bioequivalence when compared to worldwide regulatory benchmarks for systemic exposure. Although C estimates were acceptable for the majority, all generics had high max AUC prediction errors, ranging up to 51.8 % indicating potential underexposure and treatmentvariability.

Conclusions

The findings emphasize the limits of using only in vitro testing to determine therapeutic equivalency, particularly for medicines with fast absorption and broad use, such as paracetamol. Regulatory authorities should consider incorporating IVIVC-based assessments and dissolution similarity indicators into routine post-market surveillance to ensure the quality and efficacy of paracetamol products.

Zitieren

APA

Hayatu, G. I., Aishat, D. B., Adeloye, F. B., Kudirat, M. B., Jumoke, O. O., & Ajeh, I. J. (2025). In Vitro–In Vivo Correlation-Based Evaluation of Bioequivalence in Commercial Paracetamol Brands in Nigeria. The Nigerian Journal of Pharmacy, 59(2), 327-339. https://doi.org/10.51412/psnnjp.2025.33

Vancouver

Hayatu GI, Aishat DB, Adeloye FB, Kudirat MB, Jumoke OO, Ajeh IJ. In Vitro–In Vivo Correlation-Based Evaluation of Bioequivalence in Commercial Paracetamol Brands in Nigeria. The Nigerian Journal of Pharmacy. 2025;59(2):327-339. doi:10.51412/psnnjp.2025.33

BibTeX
@article{Hayatu2025,
  author = {Hayatu, Galadima Isa and Aishat, Durojaye Bisoye and Adeloye, Folashade Blessing and Kudirat, Mustapha Bolanle and Jumoke, Olayemi Olubunmi and Ajeh, Isaac Johnson},
  title = {In Vitro–In Vivo Correlation-Based Evaluation of Bioequivalence in Commercial Paracetamol Brands in Nigeria},
  journal = {The Nigerian Journal of Pharmacy},
  year = {2025},
  volume = {59},
  number = {2},
  pages = {327--339},
  doi = {10.51412/psnnjp.2025.33}
}
Kostenlos starten →